{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:21:32Z","timestamp":1793226092500,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jfo.2024.104352","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T11:31:51Z","timestamp":1730979111000},"page":"104352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fluocinolone acetonide implant (FAci) one month after dexamethasone implant (DEXi) for chronic diabetic macular edema: 1-year results"],"prefix":"10.1016","volume":"48","author":[{"given":"Q.","family":"Lampin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Poret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6939-6793","authenticated-orcid":false,"given":"M.","family":"Gherras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6934-6531","authenticated-orcid":false,"given":"B.","family":"Jany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-7092","authenticated-orcid":false,"given":"T.H.C.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2024.104352_bib0135","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ajo.2016.09.012","article-title":"Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I Data","volume":"172","author":"Gonzales","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/OPTH.S151611","article-title":"Association of treatment adherence with real life VA outcomes in AMD, DME and BRVO patients","volume":"12","author":"Ehlken","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0145","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1177\/11206721221080288","article-title":"Fluocinolone acetonide implant in diabetic macular edema: International experts\u2019 panel consensus guidelines and treatment algorithm","volume":"32","author":"Kodjikian","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/iovs.17-22259","article-title":"Pharmacology of corticosteroids for diabetic macular edema","volume":"59","author":"Whitcup","year":"2018","journal-title":"Invest Opthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2024.104352_bib0155","doi-asserted-by":"crossref","first-page":"448","DOI":"10.5301\/ejo.5000581","article-title":"Efficacy of dexamethasone intravitreal implant for the treatment of diabetic macular edema","volume":"25","author":"Bonnin","year":"2015","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0160","first-page":"135","article-title":"Safety of intravitreal dexamethasone implant (OZURDEX): the SAFODEX study. Incidence and risk factors of ocular hypertension","volume":"37","author":"Malcle's","year":"2017","journal-title":"Retina Phila Pa"},{"key":"10.1016\/j.jfo.2024.104352_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104352_bib0170","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ophtha.2012.09.014","article-title":"Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104352_bib0175","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/bjophthalmol-2018-312284","article-title":"Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries","volume":"103","author":"Chakravarthy","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0180","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2147\/OPTH.S283561","article-title":"Real-world outcomes in diabetic macular Edema for the 0.2\u00a0\u03bcg\/Day fluocinolone acetonide implant: case series from the Midlands, UK","volume":"15","author":"Bailey","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0185","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.oret.2017.10.016","article-title":"The pattern of recurrence in diabetic macular edema treated by dexamethasone implant: the PREDIAMEX study","volume":"2","author":"Bellocq","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2024.104352_bib0190","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3390\/pharmaceutics14112391","article-title":"Management of patients with diabetic macular edema switched from dexamethasone intravitreal implant to fluocinolone acetonide intravitreal implant","volume":"14","author":"Baillif","year":"2022","journal-title":"Pharma Ceutics"},{"key":"10.1016\/j.jfo.2024.104352_bib0195","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/pharmaceutics13010072","article-title":"Real world efficacy and safety of fluocinolone acetonide implant for diabetic macular edema: a systematic review","volume":"13","author":"Kodjikian","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jfo.2024.104352_bib0200","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41433-021-01542-w","article-title":"Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft\u00ae audit study","volume":"36","author":"Bailey","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2024.104352_bib0205","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s40123-023-00749-2","article-title":"Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study","volume":"12","author":"Rousseau","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"3","key":"10.1016\/j.jfo.2024.104352_bib0210","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/jamaophthalmol.2015.5346","article-title":"Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment","volume":"134","author":"Bressler","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.jfo.2024.104352_bib0215","doi-asserted-by":"crossref","first-page":"e000271","DOI":"10.1136\/bmjophth-2019-000271","article-title":"Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema","volume":"4","author":"Schechet","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"issue":"6","key":"10.1016\/j.jfo.2024.104352_bib0220","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjophthalmol-2015-306823","article-title":"Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials","volume":"100","author":"Danis","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0225","first-page":"3232","article-title":"The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexam ethasone implant in diabetic macular oedema","volume":"35","author":"Cicinelli","year":"2021","journal-title":"Eye Lond Engl"},{"issue":"11","key":"10.1016\/j.jfo.2024.104352_bib0230","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3390\/pharmaceutics14112391","article-title":"Management of patients with diabetic macular edema switched from dexamethasone intravitreal implant to fluocinolone acetonide intravitreal implant","volume":"14","author":"Baillif","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jfo.2024.104352_bib0235","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/IAE.0000000000000443","article-title":"Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema","volume":"35","author":"Scaramuzzi","year":"2015","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.jfo.2024.104352_bib0240","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00592-019-01439-x","article-title":"Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluo cinolone acetonide intravitreal implant following anti-VEGF treatment","volume":"57","author":"Rehak","year":"2020","journal-title":"Acta Diabetol"},{"issue":"4","key":"10.1016\/j.jfo.2024.104352_bib0245","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/pharmaceutics14040723","article-title":"Efficacy and safety of intravitreal fluocinolone acetonide implant for chronic diabetic macular edema previously treated in real-life practice: the REALFAc Study","volume":"14","author":"Mathis","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jfo.2024.104352_bib0250","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1089\/jop.2018.0007","article-title":"Evaluation of efficacy and safety of dexamethasone intravitreal implants of vitrectomized and nonvitrectomized eyes in a Real-World Study","volume":"34","author":"Rezkallah","year":"2018","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2024.104352_bib0255","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2147\/OPTH.S304030","article-title":"One-year outcome of aflibercept intravitreal injection in vitrectomized eyes with diabetic macular edema","volume":"15","author":"Tran","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104352_bib0260","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/OPTH.S352152","article-title":"Two-year outcome of intravitreal aflibercept injection in vitrectomized eyes with diabetic macular edema","volume":"16","author":"Tran","year":"2022","journal-title":"Clin Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224002973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224002973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T16:46:40Z","timestamp":1737650800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551224002973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0181551224002973"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104352","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluocinolone acetonide implant (FAci) one month after dexamethasone implant (DEXi) for chronic diabetic macular edema: 1-year results","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104352"}}